688091.SH
上海谊众
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 36.96
−7.65%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
107.9x
Market Cap
CNY 7.64B
MomentumView details →
1D Return
−7.65%
YTD Return
—
RSI (14)
51.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
107.9x
Market Cap
CNY 7.64B
RSI (14)
51.0
MomentumView details →
1D Return
−7.65%
YTD Return
—
Similar companies
Latest newsMore news →
Shanghai Yizhong announced its H1 2026 results: revenue of 166 million yuan, up 3.45% year-on-year; net profit attributable to shareholders of 42.3036 million yuan, up 11.31% year-on-year.11d agoShanghai Yizhong received approval from China's National Medical Products Administration for the clinical trial of its investigational drug YXC-002 for non-small cell lung cancer.17d agoShanghai Yizhong's wholly-owned subsidiary Shanghai Youxi Chuang Pharmaceutical Technology received a drug clinical trial approval notice from China's National Medical Products Administration for its self-developed innovative drug YXC-001 (a trifunctional antibody fusion protein) for the treatment of advanced solid tumors.19d ago